Abstract |
Leukopenia is frequently observed in the setting of solid organ transplantation. The risk factors, natural history, and outcomes associated with leukopenia post- transplantation have not been well defined. We retrospectively studied 102 adult kidney and/or pancreas transplant recipients over a one-yr period of time. By defining leukopenia as a white blood cell count < or =3000 cells/mm(3) and neutropenia as an absolute neutrophil count < or =2000/mm(3), the combined incidence of either leukopenia or neutropenia was 58% (59/102); the first episode occurred at a mean of 91 d post-transplant. A significant increase in the incidence of leukopenia was found in patients who either received alemtuzumab induction (42% with alemtuzumab vs. 9% with rabbit anti-thymocyte globulin induction, p < 0.05) and/or had rapid steroid withdrawal in the early post-transplant period (44% with vs. 16% without steroid withdrawal, p < 0.05). The most common intervention performed for leukopenia was reducing the dose of mycophenolate mofetil and/or valganciclovir. When granulocyte stimulating factors were used, a mean of 3.1 doses were needed to successfully manage the leukopenia. Although leukopenia was a common finding in our study of kidney and/or pancreas transplant recipients, there was no difference in the rates of infection or acute rejection in patients with and without leukopenia.
|
Authors | Erica L Hartmann, Mandy Gatesman, Julie Roskopf-Somerville, Robert Stratta, Alan Farney, Aimee Sundberg |
Journal | Clinical transplantation
(Clin Transplant)
2008 Nov-Dec
Vol. 22
Issue 6
Pg. 822-8
ISSN: 1399-0012 [Electronic] Denmark |
PMID | 19040562
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm
- Antilymphocyte Serum
- Antineoplastic Agents
- Antiviral Agents
- Immunosuppressive Agents
- Granulocyte Colony-Stimulating Factor
- Alemtuzumab
- Valganciclovir
- Mycophenolic Acid
- Ganciclovir
|
Topics |
- Alemtuzumab
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm
(therapeutic use)
- Antilymphocyte Serum
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Antiviral Agents
(therapeutic use)
- Female
- Ganciclovir
(analogs & derivatives, therapeutic use)
- Graft Rejection
(drug therapy, epidemiology, etiology)
- Granulocyte Colony-Stimulating Factor
(therapeutic use)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Kidney Transplantation
- Leukopenia
(drug therapy, epidemiology, etiology)
- Male
- Middle Aged
- Mycophenolic Acid
(analogs & derivatives, therapeutic use)
- Pancreas Transplantation
- Postoperative Complications
(drug therapy, epidemiology, etiology)
- Retrospective Studies
- Valganciclovir
|